What does a prescriber think of biosimilars?
Author:
Publisher
Computers, Materials and Continua (Tech Science Press)
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10269-011-2015-y.pdf
Reference26 articles.
1. Aapro M, Cornes P, Abraham I (2011) Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract [in press]
2. Aapro M, Van Erps J, MacDonald K, et al (2009) Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. Eur J Cancer 45(1): 8–11
3. Aapro M, Van Erps J, MacDonald K, et al. (2008) Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines. Crit Rev Oncol Hematol 65: 32–42.
4. Aapro MS, Bohlius J, Cameron DA, et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1): 8–32
5. Almenar D, Mayans D, Juan O, et al. (2009) Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain — results of the LEARN study. Eur J Cancer Care 18: 280–286
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases;Seminars in Arthritis and Rheumatism;2022-08
2. Biosimilar uptake by British local formularies: a cross sectional study;International Journal of Clinical Pharmacy;2017-09-04
3. Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies;Frontiers in Pharmacology;2016-06-29
4. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?;The European Journal of Health Economics;2013-11-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3